Gilead, Cipla partner on remdesivir expansion

By Jenni Spinner contact

- Last updated on GMT

(Image: Maksim Tkachenko)
(Image: Maksim Tkachenko)

Related tags: Gilead, Manufacturing, COVID-19, Coronavirus

The two companies will join forces on wider manufacturing and distribution of the investigational drug, granted an EUA to treat COVID-19 patients.

Under the agreement, Mumbai-based Cipla will manufacture the active pharmaceutical ingredient (API) as well as finished product, marketing it under its brand name in 127 countries. In turn, Gilead Sciences will offer manufacturing expertise on manufacturing the API and product on a commercial scale.

The emergency use authorization (EUA) recently issued by the US Food and Drug grants expanded use of remdesivir to treat hospitalized COVID-19 patients suffering from severe symptoms. The EUA is built on data from two clinical trials: the US National Institute for Allergy and Infectious Diseases’ placebo-controlled Phase III study in patients with moderate to severe symptoms of COVID-19, and Gilead’s Phase III study evaluating the drug for patients with severe disease.

Additionally, numerous additional clinical trials are underway in different parts of the globe to assemble more data regarding remdesivir’s safety and efficacy as a COVID-19 treatment. To date, the drug continues to be an investigational treatment and has not received FDA approval.

According to Cipla CEO Umang Vohra, collaborations such as the one between his firm and Gilead, are necessary to defeat the pandemic-causing virus.

“As the world is faced with the COVID-19 crisis, it is imperative that we collaborate and fight this virus together​,” he said. “We are pleased to partner with Gilead for this cause and take this treatment to patients across countries after the required regulatory approvals​.”

At Cipla, it is our continuous endeavor to ensure that no patient is denied access to life-saving treatments,​” he added. “Our partnership with Gilead represents this unwavering commitment and is a significant step towards saving millions of lives impacted by the pandemic​.”

In late March, Gilead rescinded its application to receive orphan status for remdesivir​ as a potential COVID-19 treatment.

Related news

Related products

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

What do big pharma companies spend on R&D?

What do big pharma companies spend on R&D?

Zymewire | 15-Aug-2019 | Technical / White Paper

The free Big Pharma R&D Spend report examines the financial performance and research & development investments of the top 25 pharmaceutical companies...

Related suppliers

Follow us

Products

View more

Webinars